A recent clinical trial testing the combination of cobimetinib with anti-PDL-1 therapy in 22 metastasized CRC patients with mutated KRAS and one with wildtype KRAS, resulted in four partial responders [118]. The gene discussed is KRAS; the disease is colorectal carcinoma.